{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:07:39Z","timestamp":1794938859610,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is important in the process of inflammation and fibrosis. The adenosine 5\u2032-monophosphate-activated protein kinase (AMPK) enzyme can affect JAK\/STAT pathway. Tofacitinib is a pan-JAK inhibit\u00f6r. Metformin activates AMPK enzyme. We aimed to investigate the therapeutic efficacy of tofacitinib and metformin on IL-17 and TGF-\u03b2 cytokines, skin fibrosis and inflammation in mouse model of systemic sclerosis (SSc). 40 Balb\/c female mice were divided into 4 groups: (control, sham (BLM), tofacitinib and metformin). The mice in the tofacitinib group received oral tofacitinib (20\u00a0mg\/kg\/daily) and mice in the metformin group received oral metformin (50\u00a0mg\/kg\/day) for 28\u00a0days. At the end of 4th week, all groups of mice were decapitated and tissue samples were taken for analysis. Histopathological analysis of skin tissue was performed, and mRNA expressions of collagen 3A, IL-17 and TGF-\u03b2 were assessed by real-time PCR and ELISA. Repeated BLM injections had induced dermal fibrosis. Moreover, the tissue levels of collagen 3A, IL-17 and TGF-\u03b2 were elevated in the BLM group. Tofacitinib and metformin mitigated dermal fibrosis. They reduced dermal thickness and tissue collagen 3A, IL-17 and TGF-\u03b2 levels. Tofacitinib and metformin demonstrated anti-inflammatory and anti-fibrotic effects in the mouse model of SSc.<\/jats:p>","DOI":"10.1038\/s41598-022-06581-1","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T11:03:01Z","timestamp":1644922981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Ahmet","family":"Karatas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynel Abidin","family":"Akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan Fazil","family":"Akkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru Onalan","family":"Etem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adile Ferda","family":"Dagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleyman Serdar","family":"Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"6581_CR1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Primers. 1, 15002. https:\/\/doi.org\/10.1038\/nrdp.2015 (2015).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"6581_CR2","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3390\/jcm9092687","volume":"9","author":"Y Asano","year":"2020","unstructured":"Asano, Y. The pathogenesis of systemic sclerosis: An understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies. J. Clin. Med. 9, 2687. https:\/\/doi.org\/10.3390\/jcm9092687 (2020).","journal-title":"J. Clin. Med."},{"key":"6581_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga, J., Trojanowska, M. & Kuwana, M. Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities. J. Scleroderma Relat. Disord. 2, 137\u2013152. https:\/\/doi.org\/10.5301\/jsrd.5000249 (2017).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"6581_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O\u2019Shea, J. J. et al. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu. Rev. Med. 66, 311\u2013328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537 (2015).","journal-title":"Annu. Rev. Med."},{"key":"6581_CR5","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees, C. et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum. 64, 3006\u20133015. https:\/\/doi.org\/10.1002\/art.34500 (2012).","journal-title":"Arthritis Rheum."},{"key":"6581_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2397198319865367","volume":"5","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J. Scleroderma Relat. Disord. 5, 40\u201350. https:\/\/doi.org\/10.1177\/2397198319865367 (2020).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"6581_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2019.11.013","volume":"101","author":"KW Finnson","year":"2020","unstructured":"Finnson, K. W., Almadani, Y. & Philip, A. Non-canonical (non-SMAD2\/3) TGF-\u03b2 signaling in fibrosis: Mechanisms and targets. Semin. Cell Dev. Biol. 101, 115\u2013122. https:\/\/doi.org\/10.1016\/j.semcdb.2019.11.013 (2020).","journal-title":"Semin. Cell Dev. Biol."},{"key":"6581_CR8","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly, S., Ciechomska, M., Cant, R. & van Laar, J. M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J. Biol. Chem. 289, 9952\u20139960. https:\/\/doi.org\/10.1074\/jbc.M113.545822 (2014).","journal-title":"J. Biol. Chem."},{"key":"6581_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You, H. et al. JAK inhibitors: Prospects in connective tissue diseases. Clin. Rev. Allergy Immunol. 59, 334\u2013351. https:\/\/doi.org\/10.1007\/s12016-020-08786-6 (2020).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"6581_CR10","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark, J. D., Flanagan, M. E. & Telliez, J. B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J. Med. Chem. 57, 5023\u20135038. https:\/\/doi.org\/10.1021\/jm401490p (2014).","journal-title":"J. Med. Chem."},{"key":"6581_CR11","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.3390\/ijms21155203","volume":"21","author":"E Huang","year":"2020","unstructured":"Huang, E. et al. The roles of immune cells in the pathogenesis of fibrosis. Int. J. Mol. Sci. 21, 5203. https:\/\/doi.org\/10.3390\/ijms21155203 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"6581_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.phrs.2017.10.001","volume":"128","author":"C Speirs","year":"2018","unstructured":"Speirs, C., Williams, J. J. L., Riches, K., Salt, I. P. & Palmer, T. M. Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?. Pharmacol. Res. 128, 88\u2013100. https:\/\/doi.org\/10.1016\/j.phrs.2017.10.001 (2018).","journal-title":"Pharmacol. Res."},{"key":"6581_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10753-011-9380-y","volume":"35","author":"SS Koca","year":"2012","unstructured":"Koca, S. S. et al. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation 35, 810\u2013817. https:\/\/doi.org\/10.1007\/s10753-011-9380-y (2012).","journal-title":"Inflammation"},{"key":"6581_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1124\/jpet.113.209304","volume":"348","author":"ME Dowty","year":"2014","unstructured":"Dowty, M. E. et al. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 348, 165\u2013173. https:\/\/doi.org\/10.1124\/jpet.113.209304 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"6581_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000381643","volume":"24","author":"M Kinaan","year":"2015","unstructured":"Kinaan, M., Ding, H. & Triggle, C. R. Metformin: An old drug for the treatment of diabetes but a new drug for the protection of the endothelium. Med. Princ. Pract. 24, 401\u2013415. https:\/\/doi.org\/10.1159\/000381643 (2015).","journal-title":"Med. Princ. Pract."},{"key":"6581_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/10520295.2014.977949","volume":"90","author":"S Aydin","year":"2015","unstructured":"Aydin, S. et al. Alteration of serum and cardiac tissue adropin, copeptin, irisin and TRPM2 expressions in DOX treated male rats. Biotech Histochem. 90, 197\u2013205. https:\/\/doi.org\/10.3109\/10520295.2014.977949 (2015).","journal-title":"Biotech Histochem."},{"key":"6581_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108. https:\/\/doi.org\/10.1038\/nprot.2008.73 (2008).","journal-title":"Nat. Protoc."},{"key":"6581_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neulet.2017.07.017","volume":"656","author":"\u0130 Buran","year":"2017","unstructured":"Buran, \u0130, Etem, E. \u00d6., Tektemur, A. & Elyas, H. Treatment with TREK1 and TRPC3\/6 ion channel inhibitors upregulates microRNA expression in a mouse model of chronic mild stress. Neurosci. Lett. 656, 51\u201357. https:\/\/doi.org\/10.1016\/j.neulet.2017.07.017 (2017).","journal-title":"Neurosci. Lett."},{"key":"6581_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/rheumatology\/kex362","volume":"57","author":"K Morrisroe","year":"2018","unstructured":"Morrisroe, K. et al. Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. Rheumatology (Oxford) 57, 73\u201383. https:\/\/doi.org\/10.1093\/rheumatology\/kex362 (2018).","journal-title":"Rheumatology (Oxford)"},{"key":"6581_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.trsl.2021.01.001","volume":"231","author":"FA Mendoza","year":"2021","unstructured":"Mendoza, F. A., Piera-Velazquez, S. & Jimenez, S. A. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Transl. Res. 231, 139\u2013158. https:\/\/doi.org\/10.1016\/j.trsl.2021.01.001 (2021).","journal-title":"Transl. Res."},{"key":"6581_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty, D. et al. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat. Commun. 8, 1130. https:\/\/doi.org\/10.1038\/s41467-017-01236-6 (2017).","journal-title":"Nat. Commun."},{"key":"6581_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","volume":"15","author":"F Seif","year":"2017","unstructured":"Seif, F. et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun. Signal. 15, 23. https:\/\/doi.org\/10.1186\/s12964-017-0177-y (2017).","journal-title":"Cell Commun. Signal."},{"key":"6581_CR23","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao, L., Zhang, H. & Chan, L. S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2, e24137. https:\/\/doi.org\/10.4161\/jkst.24137 (2013).","journal-title":"JAKSTAT."},{"key":"6581_CR24","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1210\/jc.2016-1882","volume":"101","author":"S Fang","year":"2016","unstructured":"Fang, S. et al. IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J. Clin. Endocrinol. Metab. 101, 2955\u20132965. https:\/\/doi.org\/10.1210\/jc.2016-1882 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6581_CR25","doi-asserted-by":"publisher","first-page":"27149","DOI":"10.1038\/srep27149","volume":"6","author":"NL Millar","year":"2016","unstructured":"Millar, N. L. et al. IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. Sci. Rep. 6, 27149. https:\/\/doi.org\/10.1038\/srep27149 (2016).","journal-title":"Sci. Rep."},{"key":"6581_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","volume":"101","author":"WW Aung","year":"2021","unstructured":"Aung, W. W. et al. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. J. Dermatol. Sci. 101, 174\u2013184. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.12.007 (2021).","journal-title":"J. Dermatol. Sci."},{"key":"6581_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1096\/fj.15-273953","volume":"30","author":"M Pedroza","year":"2016","unstructured":"Pedroza, M. et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J. 30, 129\u2013140. https:\/\/doi.org\/10.1096\/fj.15-273953 (2016).","journal-title":"FASEB J."},{"key":"6581_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843\u2013862. https:\/\/doi.org\/10.1038\/nrd.2017.201 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6581_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/03009742.2017","volume":"47","author":"T Komai","year":"2018","unstructured":"Komai, T., Shoda, H., Hanata, N. & Fujio, K. Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis. Scand. J. Rheumatol. 47, 505\u2013506. https:\/\/doi.org\/10.1080\/03009742.2017 (2018).","journal-title":"Scand. J. Rheumatol."},{"key":"6581_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/annrheumdis-2020-eular.4754","volume":"79","author":"R Karalilova","year":"2020","unstructured":"Karalilova, R. et al. Fr\u01310228 tofac\u0131t\u0131n\u0131b \u0131n the treatment of sk\u0131n and musculoskeletal \u0131nvolvement \u0131n adult pat\u0131ents w\u0131th early system\u0131c scleros\u0131s, evaluated by ultrasound. Ann. Rheum. Dis. 79, 697 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"6581_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa613","author":"H You","year":"2020","unstructured":"You, H. et al. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) https:\/\/doi.org\/10.1093\/rheumatology\/keaa613 (2020).","journal-title":"Rheumatology (Oxford)"},{"key":"6581_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/17512433.2020.1832466","volume":"13","author":"B Fallet","year":"2020","unstructured":"Fallet, B. & Walker, U. A. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Rev. Clin. Pharmacol. 13, 1203\u20131218. https:\/\/doi.org\/10.1080\/17512433.2020.1832466 (2020).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"6581_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/1440-1681.12622","volume":"43","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Exacerbated cardiac fibrosis induced by \u03b2-adrenergic activation in old mice due to decreased AMPK activity. Clin. Exp. Pharmacol. Physiol. 43, 1029\u20131037. https:\/\/doi.org\/10.1111\/1440-1681.12622 (2016).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"6581_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jdermsci.2017.04.013","volume":"87","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway. J. Dermatol. Sci. 87, 149\u2013158. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.04.013 (2017).","journal-title":"J. Dermatol. Sci."},{"key":"6581_CR35","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","volume":"105","author":"M Battaglia","year":"2005","unstructured":"Battaglia, M., Stabilini, A. & Roncarolo, M. G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743\u20134748. https:\/\/doi.org\/10.1182\/blood-2004-10-3932 (2005).","journal-title":"Blood"},{"key":"6581_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.intimp.2013.03.020","volume":"16","author":"KY Kang","year":"2013","unstructured":"Kang, K. Y. et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int. Immunopharmacol. 16, 85\u201392. https:\/\/doi.org\/10.1016\/j.intimp.2013.03.020 (2013).","journal-title":"Int. Immunopharmacol."},{"key":"6581_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lfs.2015.01.042","volume":"127","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Activation of AMPK by metformin inhibits TGF-\u03b2-induced collagen production in mouse renal fibroblasts. Life Sci. 127, 59\u201365. https:\/\/doi.org\/10.1016\/j.lfs.2015.01.042 (2015).","journal-title":"Life Sci."},{"key":"6581_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molimm.2019.07.002","volume":"114","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg\/Teff cells and reducing spleen germinal center formation. Mol. Immunol. 114, 72\u201380. https:\/\/doi.org\/10.1016\/j.molimm.2019.07.002 (2019).","journal-title":"Mol. Immunol."},{"issue":"9","key":"6581_CR39","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.jid.2016.05.097","volume":"136","author":"F Ursini","year":"2016","unstructured":"Ursini, F. et al. Oral metformin ameliorates bleomycin-induced skin fibrosis. J. Investig. Dermatol. 136(9), 1892\u20131894. https:\/\/doi.org\/10.1016\/j.jid.2016.05.097 (2016).","journal-title":"J. Investig. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06581-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06581-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06581-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:07:21Z","timestamp":1669331241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06581-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6581"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06581-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"5 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2553"}}